<DOC>
	<DOCNO>NCT02603510</DOCNO>
	<brief_summary>Primary Objective : - Assess safety SAR342434 Humalog use external pump . Secondary Objectives : - Intervals infusion set change . - Incidence insulin pump alarm infusion set occlusion . - Patient observation infusion set occlusion . - Adverse event include bruise infusion site injection site reaction .</brief_summary>
	<brief_title>Assessment Safety SAR342434 Humalog® When Administered Continuous Subcutaneous Insulin Infusion</brief_title>
	<detailed_description>The study duration patient approximately 10 week .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 1</mesh_term>
	<mesh_term>Insulin , Globin Zinc</mesh_term>
	<mesh_term>Insulin</mesh_term>
	<mesh_term>Insulin Lispro</mesh_term>
	<criteria>Inclusion criterion : Male female subject age 18 . Patients type 1 diabetes mellitus least 1 year prior screen visit . At least 1 year insulin treatment least 6 month continuous subcutaneous insulin infusion ( CSII ) treatment external insulin pump . Signed write informed consent . Exclusion criterion : HbA1c ≥8.5 % screening . Diabetes type 1 diabetes mellitus . History abscess infusion site within 3 month prior screen visit ( Visit 1 ) . Use oral glucoselowering agent injectable glucoselowering agent insulin 3 month screen . Hospitalization diabetic ketoacidosis ( DKA ) last 6 month screen visit . Hypoglycemic unawareness judge Investigator last 6 month screen visit . History severe hypoglycemia require treatment emergency room admission hospitalization last 6 month screen visit . Any clinically significant abnormality identify physical examination , laboratory test , vital sign time screen judgment investigator sub investigator would preclude safe completion study . Known history drug alcohol abuse within 6 month prior time screen . Use investigational drug ( ) within 3 month 5 halflives , whichever longer , prior screen visit . Patients previously receive SAR342434 clinical trial . Pregnancy lactation : Women child bear potential ( WOCPB ) ( premenopausal , surgically sterile least 3 month prior time screen ) use highly effective ( ie , low failure rate &lt; 1 % per year ) method ( ) birth control throughout study and/or unwilling tested pregnancy . Any contraindication use Humalog define national product label ; history hypersensitivity Humalog excipients . Patients employee relative employee Sponsor . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>